Voruciclib

Drug Profile

Voruciclib

Alternative Names: P-1446A-05; P1446

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Piramal Life Sciences
  • Developer Dana-Farber Cancer Institute; Norris Cotton Cancer Center; Piramal Enterprises
  • Class Small molecules
  • Mechanism of Action Cyclin-dependent kinase 4 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Chronic lymphocytic leukaemia; Malignant melanoma
  • No development reported Cancer

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Cancer(Late-stage disease, Second-line therapy or greater) in Canada (PO, Capsule)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Cancer(Late-stage disease, Second-line therapy or greater) in India (PO, Capsule)
  • 19 Apr 2016 Preclinical data in Cancer presented at the 107th Annual Meeting of the American Association for Cancer Research (AACR-2016) (9194542; 3182655)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top